CD8A and neoplasm: By interacting with ligands with its ligands CD155, PVRL3, and CD112, TIGIT blocks NK cell-mediated tumor killing, activates immunosuppressive DCs, decreases CD8 T-cell initiation and differentiation, and inhibits CD8 T cell-mediated tumor killing, thus causing immunosuppression.